Inclusion Criteria:  Age >=20 years old; History of chronic hepatitis B with HBsAg-positive; Both HBeAg-positive and HBeAg-negative are allowed; Inflammatory arthritis (including psoriatic arthritis); On bDMARDs treatment or will start bDMARDs within in 4 weeks. The bDMARDs included all anti-TNF-α agents, rituximab (anti-CD20 monoclonal antibody), tocilizumab (anti-interleukin 6 receptor monoclonal antibody), abatacept (cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin), and all new biologics with indication of IA treatment; No NUCs treatment in recent 6 months; No limitation of the baseline HBV DNA level; Total bilirubin level <2 mg/dL; ALT < 2x ULN (<80 U/L).  Exclusion Criteria:  Child-Pugh class >B7; Active EV bleeding within 4 weeks; History of hepatic encephalopathy or intractable ascites; Coexist with other primary liver diseases, such as active chronic hepatitis C, hepatitis D, autoimmune hepatitis, or Wilson's disease. (*HCV RNA undetectable is allowed to enroll); Active malignancy; Pregnant women.